Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study.

Ketian LiXuan QiYuan LiQing WuQun ShiLi WangJing LiLidan ZhaoLi ZhangXinyao ZhouYunyun FeiJinjing LiuJinmei SuDi WuYunjiao YangHui JiangXiaofeng ZengFengchun ZhangYan Zhao

Published in: Modern rheumatology (2020)

In this study, iguratimod treatment is safe and effective for improving disease activity and laboratory parameters in early pSS patients.

Keyphrases

disease activity
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes